Focused On-demand Library for Serine palmitoyltransferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Long chain base biosynthesis protein 2; Long chain base biosynthesis protein 2a; Serine-palmitoyl-CoA transferase 2

Alternative UPACC:

O15270; Q16685


Serine palmitoyltransferase 2 (SPTLC2) plays a pivotal role in de novo sphingolipid biosynthesis, essential for adipogenesis. This enzyme, forming a heterodimer with SPTLC1, exhibits substrate preference influenced by its complex composition; the SPTLC1-SPTLC2-SPTSSA complex favors C16-CoA, while the SPTLC1-SPTLC2-SPTSSB complex prefers C18-CoA.

Therapeutic significance:

SPTLC2 mutations lead to hereditary sensory and autonomic neuropathy 1C (HSAN1C), characterized by sensory abnormalities and severe infections. These mutations alter SPT's substrate specificity, causing the production of 1-deoxysphingolipids, which are toxic due to improper metabolism. Understanding SPTLC2's role could unveil new therapeutic strategies for HSAN1C.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.